^
Association details:
| Biomarker: | CD79B mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | safimaltib (JNJ-6633) (MALT1 protein inhibitor) + JNJ-4681 (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DISCOVERY AND PRECLINICAL PROPERTIES OF JNJ-64264681, A POTENT AND SELECTIVE COVALENT BTK INHIBITOR FOR THE TREATMENT OF B CELL MALIGNANCIES
Published date:
05/12/2021
Excerpt:
Treatment with the combination of JNJ-64264681 and the MALT1 inhibitor JNJ-67856633 resulted in increased tumor growth inhibition compared with single agents and tumor regression in both CD79b mutant mouse lymphoma models.
Source:
Title:
1267 - Combination therapy of JNJ-67856633, a novel, first-in-class MALT1 protease inhibitor, and JNJ-64264681, a novel BTK inhibitor, for the treatment of B-cell lymphomas
Published date:
03/10/2021
Excerpt:
Treatment with JNJ-64264681 and JNJ-67856633 administered together demonstrated statistically significant tumor growth inhibition compared with vehicle control in two CD79b mutant mouse lymphoma models, one based on a DLBCL cell line (OCI-Ly10) and one based on a patient-derived DLBCL model (LY2298). In both models, the combination showed increased growth inhibition compared with single agents and tumor regression in the combination arm. Synergistic anti-proliferative activity was observed in three DLBCL cell lines carrying CD79b mutations...the in vitro and in vivo data for JNJ‑67856633 and JNJ-64264681 suggest that combination therapy can increase the anti-tumor effect of the monotherapies and provide a more sustained response...
